![\"\"](\"https:\/\/images.newsfilecorp.com\/files\/9113\/268092_79f8c45f544aea61_001full.jpg\")
<\/a> <\/p>\nDr. Bob Miller delivering his keynote presentation at the MAPS 2025 Annual Conference in Phoenix, Arizona.<\/p>\n
To view an enhanced version of this graphic, please visit: Unlocking the Core of Neuroinflammation in ASD<\/b><\/p>\n Dr. Miller explained that chronic neuroinflammation in Autism Spectrum Disorder (ASD) is driven by overactivation of the NLRP3 inflammasome<\/b>. This mechanism, described as the “triple positive feedback storm,”<\/b> shows how genetic vulnerabilities can combine with environmental toxins such as heavy metals, microplastics, glyphosate, and mold exposure to fuel brain inflammation.<\/p>\n Miller shared new genetic insights: among 36 children tested, 59% carried mutations in the NLRP3 pathway<\/b>, with 67% showing ELOVL2 mutations<\/b> affecting fatty acid metabolism. Variants in NQO1, NRF2, and KEAP1<\/b> were also highlighted, weakening antioxidant defenses and leaving children more vulnerable to oxidative stress. He noted that 22% carried both NQO1 and KEAP1 variants<\/b>, underscoring the need for individualized antioxidant support.<\/p>\n Vitamin-related pathways were also emphasized. 72% of participants carried variations in the vitamin D receptor<\/b>, indicating that supplementation strategies must be personalized rather than one-size-fits-all. Meanwhile, 31% had NF-\u03baB pathway variants<\/b>, amplifying inflammatory responses.<\/p>\n Miller further addressed environmental toxins, pointing to Ochratoxin<\/b>, a common mold toxin, as a potent activator of both NLRP3 and NF-\u03baB. He stressed the importance of detoxification enzymes like UGT and GST, whose activity can be impaired by genetic variants.<\/p>\n On energy metabolism, he described how genes such as NQO1, NRF2, KEAP1, and CD38<\/b> influence the NAD cycle, warning that poorly regulated supplementation may worsen imbalances. He also unveiled new findings on hydrogen sulfide (H\u2082S)<\/b>, a signaling molecule tied to mitochondrial function and oxidative stress, suggesting its emerging role in ASD.<\/p>\n Story Continues <\/p>\n The PEARL Study: Clinical Validation of Precision Nutrition<\/b><\/p>\n Supporting his hypotheses, Dr. Miller’s team collaborated with Purdue University to conduct the PEARL Study<\/b> (Personalized Nutrition, Education, Assessment, “Real” Food, and Lifestyle Support). The study enrolled 36 individuals with ASD, all carrying key genetic variants.<\/p>\n The personalized protocol combined an organic whole-foods diet, targeted supplementation tailored to genetic needs, and lifestyle education. Outcomes confirmed improvements in detoxification markers, inflammatory profiles, and neurological resilience-validating that precision nutrition can directly address genetic vulnerabilities.<\/b><\/p>\n AI-Powered Genomics Meets Personalized Health<\/b><\/p>\n Dr. Miller introduced the FGA AI System<\/b>, capable of analyzing over 260,000 genomic markers<\/b> to produce personalized reports and nutrient protocols. Integrated with a dedicated North American manufacturing facility, it enables true “one person, one formula” solutions.<\/p>\n “This platform represents the future of medicine,” Dr. Miller said. “By aligning genes, environment, and nutrition, we can transform how complex conditions like autism are addressed.”<\/p>\n A Ten-Step Strategy and Future Outlook<\/b><\/p>\n In closing, Dr. Miller proposed a ten-step intervention strategy<\/b> covering antioxidant support, inflammation control, fatty acid and nucleic acid balance, NAD cycle optimization, and toxin clearance. He emphasized that genetic testing is not only a research tool but also the foundation for future individualized clinical care.<\/p>\n The presentation was met with strong praise from attendees, who described it as both scientifically rigorous and clinically actionable. Miller’s phrase – “Your best friend, unless it becomes your worst enemy” – became one of the most cited remarks of the conference, highlighting the dual role of immune pathways in health and disease.<\/p>\n From left to right – Penny Wu, President of the Canadian National Precision Nutrition Association; Dr. Bob Miller, Founder of the NutriGenetic Research Institute (NGRI); and Yvonne Lucchese, General Manager of the FGA Platform, at the MAPS Fall 2025 Conference in Phoenix, Arizona.<\/p>\n To view an enhanced version of this graphic, please visit: About Dr. Bob Miller and the FGA Platform<\/b><\/p>\n Dr. Bob Miller is a pioneer in functional genomics and precision nutrition with more than 30 years of research experience. As founder of the NutriGenetic Research Institute (NGRI)<\/b> and developer of the Functional Genomic Analysis (FGA) Platform<\/b>, Dr. Miller has advanced the understanding of gene-environment interactions in chronic disease. His work has been validated through clinical studies such as the PEARL Study and continues to shape the future of personalized healthcare worldwide.<\/p>\n Contact:
https:\/\/images.newsfilecorp.com\/files\/9113\/268092_79f8c45f544aea61_001full.jpg<\/a><\/p>\n
https:\/\/images.newsfilecorp.com\/files\/9113\/268092_79f8c45f544aea61_002full.jpg<\/a><\/p>\n
BioDecode International Medical Research Co.,Ltd
https:\/\/edu.idhealth.cn\/<\/a>
Shuang Wu
wushuang@naturespan.com<\/a><\/p>\n